MiNK Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

INKT$10.30-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MiNK Therapeutics, Inc.
Date: March 31, 2026	By:	/s/ Jennifer S. Buell, Ph.D.
		Jennifer S. Buell, Ph.D.
		President, Chief Executive Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Melissa Orilall
Name	Title	Date
/s/ Jennifer S. Buell, Ph.D.	President, Chief Executive Officer and Director	March 31, 2026
Jennifer S. Buell, Ph.D.	(Principal Executive Officer)
/s/ Melissa Orilall	Principal Financial Officer	March 31, 2026
/s/ Austin Charette	Principal Accounting Officer	March 31, 2026
Austin Charette
/s/ Garo H. Armen, Ph.D.	Chairman of the Board of Directors	March 31, 2026
Garo H. Armen, Ph.D.
/s/ Peter Behner	Director	March 31, 2026
Peter Behner
/s/ Brian Corvese	Director	March 31, 2026
Brian Corvese
/s/ John Holcomb, M.D.	Director	March 31, 2026
John Holcomb, M.D.
/s/ Barbara Ryan	Director	March 31, 2026
Barbara Ryan
/s/ Ulf Wiinberg	Director	March 31, 2026
Ulf Wiinberg

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.